Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.90 Average Target Price from Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $36.90.

Several analysts have weighed in on SNDX shares. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Finally, Stifel Nicolaus increased their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX opened at $12.52 on Friday. Syndax Pharmaceuticals has a 12 month low of $12.40 and a 12 month high of $25.34. The business’s 50-day moving average is $16.48 and its two-hundred day moving average is $18.96. The firm has a market capitalization of $1.07 billion, a PE ratio of -3.45 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the firm earned ($0.73) EPS. Equities analysts anticipate that Syndax Pharmaceuticals will post -2.39 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth $27,000. Values First Advisors Inc. acquired a new position in Syndax Pharmaceuticals during the 3rd quarter worth $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals during the second quarter valued at about $33,000. Finally, Inspire Investing LLC grew its position in shares of Syndax Pharmaceuticals by 15.0% in the second quarter. Inspire Investing LLC now owns 17,290 shares of the company’s stock valued at $355,000 after purchasing an additional 2,258 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).